EUVIMEDOpdag EUVIMED
EditorialKommentar

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply

Stephanie A Vuijk iD, Lissy de Ridder iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18053 ↗

At a glance

Editorial in Alimentary Pharmacology & Therapeutics, 2024. Written by Stephanie A Vuijk and 1 co-authors. Institution: Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands. Major MEDLINE topics: Crohn Disease, Infliximab, Cost-Benefit Analysis, Gastrointestinal Agents. 10 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

LINKED CONTENT This article is linked to Vuijk et al papers. To view these articles, visit https://doi.org/10.1111/apt.18000 and https://doi.org/10.1111/apt.18033

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseInfliximabCost-Benefit AnalysisGastrointestinal AgentsHumansChild

Substances

InfliximabGastrointestinal Agents

Authors and institutions

  • Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands.

ORCID profiles: Stephanie A Vuijk, Lissy de Ridder

Cite

APA

Vuijk, S. A., & de Ridder, L. (2024). Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18053

Vancouver

Vuijk SA, de Ridder L. Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18053

BibTeX
@article{Vuijk2024,
  author = {Vuijk, Stephanie A and de Ridder, Lissy},
  title = {Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18053}
}
Start for free →